Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer’s disease
Calhoun A, Ko J, Grossberg GT. Emerging chemical therapies targeting 5-hydroxytryptamine in the treatment of Alzheimer’s disease. Expert Opinion On Emerging Drugs 2017, 22: 101-105. PMID: 28253832, DOI: 10.1080/14728214.2017.1293651.Peer-Reviewed Original ResearchConceptsNMDA receptor antagonistAlzheimer's diseaseClinical trialsReceptor antagonistCurrent phase 3 trialsPhase 3 trialCurrent clinical trialsNeuronal cell deathMajor neuropsychiatric disordersSymptom pathophysiologySymptomatic treatmentAD symptomatologyClinical symptomatologyNeuritic plaquesNeurofibrillary tanglesCurrent treatmentPotential treatmentSupplementary treatmentCholinesterase inhibitorsIdalopirdineAge 65Neuropsychiatric disordersAntagonistLiterature searchDisease